10-Q: TG Therapeutics Reports Soaring Q3 Revenue, Net Income

TG Therapeutics announced a significant increase in product revenue and net income for the nine months ended September 30, 2025, driven by strong BRIUMVI sales and a substantial tax benefit.

Summary

• Total revenue for the nine months ended September 30, 2025, reached $423.7 million, a substantial increase from $220.8 million in the prior year period.
• Product revenue, net, primarily from U.S. sales of BRIUMVI, grew to $417.8 million for the nine months ended September 30, 2025, up from $206.4 million in the same period of 2024.
• Net income for the nine months ended September 30, 2025, was $424.1 million, a dramatic rise from $0.05 million in the prior year, largely due to a $361.8 million income tax benefit from the release of a deferred tax asset valuation allowance.
• Basic earnings per share (EPS) increased to $2.90 for the nine months ended September 30, 2025, compared to $0.00 in the same period of 2024.
• Research and development expenses increased to $119.0 million for the nine months ended September 30, 2025, from $70.4 million in 2024, primarily due to subcutaneous ublituximab development and increased clinical trial activities.
• Selling, general and administrative expenses rose to $169.3 million for the nine months ended September 30, 2025, from $115.3 million in 2024, driven by commercialization efforts for BRIUMVI.
• Cash and cash equivalents, along with investment securities, totaled $131.6 million as of September 30, 2025, down from $311.0 million at December 31, 2024.
• Net cash used in operating activities increased to $44.4 million for the nine months ended September 30, 2025, compared to $14.9 million in the prior year.
• The company completed its $100 million share repurchase program in September 2025, repurchasing 3,502,334 shares at an average price of $28.55 per share, and authorized a new $100 million share repurchase program.
• The license agreement for TG-1701 (BTK inhibitor) with Jiangsu Hengrui Medicine Co. and the Joint Venture and License Option agreement for TG-1801 (anti-CD47/anti-CD19) with Novimmune SA were mutually terminated in September 2025 and April 2025, respectively, with all rights reverting to the partners.

Sentiment

Score: 8

Explanation: The company demonstrated strong commercial execution with BRIUMVI, leading to a substantial increase in product revenue and a significant net income, largely boosted by a deferred tax asset valuation allowance release. Pipeline advancements for subcutaneous ublituximab and azer-cel are positive. However, cash used in operations increased, and the company acknowledges potential future financing needs and a range of industry-specific and macroeconomic risks.

Positives

• Product revenue, net, for the nine months ended September 30, 2025, significantly increased to $417.8 million from $206.4 million in the prior year, demonstrating strong commercialization of BRIUMVI.
• Net income before taxes for the nine months ended September 30, 2025, was $62.3 million, a substantial improvement from $0.1 million in the prior year, indicating operational profitability.
• The company reported a significant income tax benefit of $361.8 million for the nine months ended September 30, 2025, primarily due to the release of a deferred tax asset valuation allowance, leading to a net income of $424.1 million.
• Basic EPS rose to $2.90 and diluted EPS to $2.62 for the nine months ended September 30, 2025, reflecting improved financial performance.
• Three additional patents for BRIUMVI were issued by the USPTO on February 27, 2024, extending patent protection through 2042, enhancing intellectual property strength.
• Long-term (six-year) data from the ULTIMATE I & II Phase 3 trials for BRIUMVI were presented at ECTRIMS 2025, along with updated data from the ENHANCE trial and 2025 data from the ENABLE observational study, indicating ongoing clinical development and data generation.
• Patient enrollment commenced in August 2025 for a Phase 3 pivotal cohort evaluating a consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI in the ENHANCE trial.
• Enrollment commenced in September 2025 for the Phase 3 pivotal program evaluating subcutaneous ublituximab, aiming to expand treatment options.
• The first patient with progressive multiple sclerosis was dosed with azer-cel in a Phase 1 trial in August 2025, following FDA IND clearance in August 2024, advancing a new pipeline candidate for autoimmune diseases.
• The Board authorized a new $100 million share repurchase program in September 2025, following the completion of a prior $100 million program, signaling confidence in the company's financial position and commitment to shareholder value.

Negatives

• Cash and cash equivalents, and investment securities decreased significantly to $131.6 million as of September 30, 2025, from $311.0 million at December 31, 2024.
• Net cash used in operating activities increased to $44.4 million for the nine months ended September 30, 2025, compared to $14.9 million in the prior year, indicating higher operational cash burn.
• License, milestone, royalty and other revenue decreased to $5.9 million for the nine months ended September 30, 2025, from $14.4 million in the prior year, primarily due to a one-time $12.5 million milestone payment recognized in 2024.
• The company's accumulated deficit remains substantial at approximately $1.1 billion as of September 30, 2025, despite recent profitability.
• The termination of license agreements for TG-1701 and TG-1801 indicates a reduction in the company's pipeline of investigational medicines.
• Accounts receivable, net, increased significantly to $265.4 million as of September 30, 2025, from $129.2 million at December 31, 2024, partly due to extended payment terms offered during the BRIUMVI commercial launch, which could impact cash flow from operations.

Risks

• Failure to achieve broad market acceptance for BRIUMVI or future product candidates among physicians, patients, and healthcare payors could limit revenues.
• Regulatory approvals may be subject to limitations on indicated uses or require costly post-marketing studies, or marketing approval for BRIUMVI could be withdrawn.
• BRIUMVI or future approved products may cause undesirable side effects after commercialization, leading to negative consequences such as regulatory withdrawal, labeling restrictions, or product liability lawsuits.
• Market opportunities for BRIUMVI and other product candidates may be smaller than estimated, adversely affecting revenue and profitability.
• Substantial competition from other pharmaceutical and biotechnology companies could reduce or eliminate commercial opportunities.
• Unfavorable pricing regulations or third-party payor coverage and reimbursement policies could harm the business.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• The company has incurred substantial operating losses since inception and may incur future losses, and there is no assurance of sustained profitability.
• The company may need to raise additional capital, and inability to do so could delay, limit, reduce, or eliminate drug development programs or commercialization efforts.
• The company's level of indebtedness and debt service obligations could adversely affect its financial condition and make it difficult to fund operations.
• Failure to maintain or obtain regulatory approval for products and product candidates, or significant delays, would materially harm the business.
• Results of preclinical studies and early clinical trials are not necessarily predictive of future results, and interim data may change, potentially impacting product profiles.
• Product candidates may cause undesirable side effects, delaying or preventing regulatory approval or impacting commercial potential.
• Extensive, costly, and time-consuming regulation of drug development and approval processes.
• New legislation, regulatory proposals, and third-party payor initiatives may increase compliance costs and adversely affect marketability.
• Inadequate funding, government shutdowns, or other policy changes affecting regulatory agencies (FDA, SEC) could hinder their ability to perform normal business functions.
• Failure to adequately understand and comply with local laws and customs in international markets could lead to losses.
• Products, once approved, could be subject to restrictions or withdrawal from the market, and penalties may be imposed for non-compliance.
• Reliance on third parties for clinical, preclinical data, and clinical trials increases risks of non-performance or delays.
• Reliance on third parties for manufacturing and testing of BRIUMVI and product candidates increases risks of insufficient quantities, unacceptable cost, or quality issues.
• Sole source suppliers for starting materials, API, and drug product pose risks of loss or disruption.
• Disputes with or non-performance by licensors could adversely affect the ability to develop and commercialize products.
• Dependence on collaboration and commercialization partners (e.g., Neuraxpharm) carries risks of unsuccessful relationships or termination of agreements.
• Inability to obtain and protect intellectual property (patents, trade secrets) or challenges to their validity/enforceability could impair commercialization.
• Need to license certain intellectual property from third parties, which may not be available on commercially reasonable terms.
• Failure to protect the confidentiality of trade secrets could harm business and competitive position.
• Failure to attract and keep key management, commercial, and clinical development personnel could impede success.
• Difficulties in managing business development and expansion could disrupt operations.
• Certain executive officers, directors, and principal stockholders may exercise significant influence over the company.
• Internal information technology systems or those of third-party contractors may fail or suffer security breaches, disrupting development programs and commercialization.
• Unfavorable global economic conditions (e.g., high inflation, interest rates, tariffs, geopolitical conflicts) could adversely affect business.
• Stock price volatility is expected to continue, limiting investors' ability to sell at a profit.
• Risks related to corporate social responsibility and reputational matters.
• Climate change or measures to address it may negatively affect business, supply chain, and financial condition.
• Limitations on the ability to pay dividends.
• An active trading market for common stock may not be sustained.
• Reliance on equity research analysts; negative evaluations could cause stock price decline.
• Significant increased costs and management time required for public company compliance (Sarbanes-Oxley Act).
• Volatility in stock price may lead to securities and shareholder derivative litigation.
• Future sales of common stock could cause stock price to decline.
• The share repurchase program may not be further consummated or enhance stockholder value.
• Biologics carry unique risks and uncertainties in development, manufacturing, and sale.
• Inability to successfully develop, obtain regulatory approval for, or commercialize a subcutaneous formulation of ublituximab could limit market opportunity.
• Adoption of artificial intelligence (AI) technology may expose the company to defects, security breaches, and evolving regulatory frameworks.

Future Outlook

The company anticipates that its current cash, cash equivalents, and investment securities, combined with projected future revenues, will be sufficient to meet liquidity needs for more than twelve months from the filing date. However, it acknowledges that significant additional financing may be required in the future to support ongoing and planned operations. The company expects to continue incurring substantial research and development, commercialization, and outsourced manufacturing expenses. It also foresees continued intense political and social pressures on prescription drug pricing and healthcare costs globally, with potential for new legislation and regulatory changes impacting profitability and market access. Cybersecurity threats are expected to persist and become more sophisticated, and the full impact of geopolitical conflicts and tariffs remains uncertain.

Management Comments

• "Although we have recently achieved profitability, we have incurred substantial operating losses since our inception."
• "We anticipate that our cash, cash equivalents, and investment securities, combined with projected future revenues will be sufficient to meet our liquidity needs for more than twelve-months from the date of filing this Quarterly Report on Form 10-Q."
• "We may require significant additional financing in the future to support our ongoing and planned operations."
• "We believe there is potential market opportunity for BRIUMVI outside of the U.S., including in the EU."
• "While we currently do not believe such conflicts will have a material impact on product development or our overall business, given the evolving situation and the related geopolitical and economic uncertainties, the full impact of the conflict remains uncertain."
• "We believe that all of our marketing efforts, including our direct-to-consumer advertising, comply with FDA regulations."

Industry Context

The biopharmaceutical industry is characterized by high competition, significant capital requirements, and extensive regulatory oversight. TG Therapeutics operates within the neurological and immunological fields, specifically targeting B-cell diseases like Multiple Sclerosis. The industry faces ongoing pressures from governments and third-party payors to contain healthcare costs and reduce prescription drug prices, influenced by legislation like the ACA and IRA. There's also an increasing focus on data privacy, cybersecurity, and the evolving regulatory landscape for artificial intelligence technologies. Geopolitical conflicts and global economic instability further add complexity to supply chains and commercialization efforts.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry comparison.

Corporate Governance

Legal Proceedings

• The company and its subsidiaries are not a party to, and their property is not the subject of, any material pending legal proceedings.

Related Party Transactions

• The company has a Shared Services Agreement with Fortress Biotech, Inc. (FBIO) since July 2015, incurring approximately $1.0 million for shared personnel for the nine months ended September 30, 2025.
• The company has an Office Agreement with FBIO since October 2014, for New York City office space, with an average annual rental obligation of $1.8 million and a pledged security deposit of $1.3 million.
• Michael S. Weiss, the company's Chairman and Chief Executive Officer, also serves as a director and Executive Vice Chairman, Strategic Development of FBIO.

Stakeholder Impact

• **Shareholders**: Benefit from strong revenue growth, significant net income, and a new share repurchase program, but face risks of stock price volatility and potential future dilution from capital raises.
• **Employees**: Increased headcount and noncash compensation expense indicate growth, but the company's ability to attract and retain key personnel remains critical.
• **Customers/Patients**: Continued commercialization of BRIUMVI and advancement of pipeline candidates (subcutaneous ublituximab, azer-cel) offer new treatment options for B-cell diseases and MS, but risks related to market acceptance and side effects persist.
• **Suppliers/Creditors**: The company's reliance on single-source suppliers and its loan payable obligations highlight ongoing relationships and financial commitments.
• **Regulatory Bodies**: The company's operations are subject to extensive and evolving regulatory requirements from agencies like the FDA and SEC, requiring continuous compliance efforts.

Next Steps

• Continue commercialization of BRIUMVI in the U.S. and ex-U.S. markets.
• Advance the Phase 3 pivotal program for subcutaneous ublituximab.
• Continue patient enrollment in the Phase 3 pivotal cohort for consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI in the ENHANCE trial.
• Continue the Phase 1 trial for azer-cel in patients with progressive multiple sclerosis.
• Actively evaluate complementary products, technologies, and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
• Monitor and comply with evolving regulatory requirements, including those related to healthcare reform, drug pricing, and AI technologies.
• Manage supply chain risks and potential impacts from tariffs and geopolitical conflicts.
• Potentially seek additional financing to support ongoing and planned operations.

Key Dates

Recommendation

The company demonstrated strong commercial execution with BRIUMVI, leading to a substantial increase in product revenue and a significant net income, largely boosted by a deferred tax asset valuation allowance release. The authorization of a new share repurchase program signals confidence in future cash flows. However, the company continues to burn cash from operating activities, relies heavily on a single commercial product, and faces numerous risks inherent in the biopharmaceutical industry, including intense competition, regulatory hurdles, and dependence on third parties for manufacturing and development. While the financial results are positive, the underlying operational cash burn and the speculative nature of drug development warrant a cautious "Hold" recommendation for seasoned investors, balancing growth potential with significant inherent risks.

Keywords

Biopharmaceutical, Multiple Sclerosis, BRIUMVI, Ublituximab, B-cell diseases, CAR T therapy, Azer-cel, SEC filing, 10-Q, Financial results, Drug development, Commercialization, Clinical trials, Regulatory approval, Biotechnology, Pharmaceuticals, Stock repurchase, Intellectual property, Corporate governance, Risk management